MEI Pharma did not limit itself to buying Litecoin (LTC). It built a new strategic pillar around it. This Nasdaq-listed company raised 100 million dollars through a private placement (PIPE). What is its goal? To turn LTC into its main reserve asset. It is the first time a biopharmaceutical company has dared to make such a decision.
The event does not stop at the purchase. MEI has also welcomed Charlie Lee, the creator of Litecoin, to its board of directors. He did not mince words:
"This partnership with GSR and MEI Pharma finally brings Litecoin's mission to the institutional environment."
With GSR, a leader in crypto markets, as an advisor in digital asset management, MEI is equipped with a formidable duo. Charlie Lee, a recognized pioneer, embodies visionary leadership. GSR, for its part, directs the strategy and oversees the risks. The result: a hybrid governance between biotechnology, traditional finance, and crypto.
The announcement quickly caused a stir. Litecoin rose more than 12%. Its transaction volume exploded. The Charlie Lee effect? Surely. But also the institutional effect.
Luxxfolio Holdings, another listed player, did not remain indifferent. Since March, the company has increased its treasury in Litecoin by 151.6% per share, now reaching a total of 20,084 LTC.
